GlaxoSmithKline (GSK) and Theravance have announced the completion of patient enrolment in the SUMMIT trial designed to determine the impact of Relvar/Breo Ellipta (fluticasone furoate’FF’/vilanterol ‘VI’) in patients with moderate chronic obstructive pulmonary disease (COPD) who have cardiovascular disease (CVD) or are at increased risk for CVD.

Around 16,000 patients enrolled in the multicentre, double-blind, parallel-group, placebo-controlled SUMMIT (‘Study to Understand Mortality and MorbidITy’) trial.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The trial includes patients with moderate COPD and a history of or increased risk for cardiovascular disease who are randomised to receive either once daily treatment with fluticasone furoate/vilanterol (100/25mcg), fluticasone furoate (100mcg), vilanterol (25mcg) or placebo.

"We hope that results from this study will increase our understanding of cardiovascular comorbidity in COPD."

The primary objective of the trial is to assess the effect of FF/VI compared with placebo on survival evaluated by the primary endpoint of all-cause mortality, while the secondary endpoints are rate of decline in forced expiratory volume in 1 second (FEV) and a composite cardiovascular endpoint.

The company said that the exact duration of the treatment phase will depend on the mortality rate within the trial and it is expected that each patient will participate in the trial for between 16-53 months.

See Also:

GSK SVP and head of global respiratory Franchise Darrell Baker said: "We hope that results from this study will increase our understanding of cardiovascular comorbidity in COPD, and of the effects of Relvar/Breo Ellipta when used to manage COPD."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In May 2013, the US Food and Drug Administration (FDA) had granted license to Breo Ellipta (FF/VI 100/25mcg) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and/or emphysema.

The company said that Breo Ellipta is not indicated for the relief of acute bronchospasm or the treatment of asthma in the US.

Theravance chief executive officer Rick Winningham said: "We believe that, once available, the results from this landmark study will enhance our knowledge of these co-morbid conditions and provide important information about treatment with Relvar/Breo in a COPD population with cardiovascular risk factors."

Frequently asked questions

  • 1. How are Healthcare companies using Internet of Things (IoT) technologies?

    Healthcare companies are using IoT technologies in various ways, such as remote patient monitoring, telemedicine, digital health, wearables, and sensors. IoT tools are also used in the pharma industry, from manufacturing processes to remote patient monitoring.

  • 2. How do internet of things (IoT) technologies impact the Healthcare industry?

    IoT technologies have a significant impact on the healthcare industry, as they enable remote patient monitoring, telemedicine, and digital health solutions. IoT tools can be adopted across the entire pharma value chain to various ends, from manufacturing processes to RPM.

  • 3. Who are the top adopters of internet of things (IoT) technologies in Healthcare?

    The top adopters of IoT technologies in healthcare include Bupa, Cleveland Clinic, Roche, Pfizer, Novartis, Medtronic, Boston Scientific, Royal Philips, and GE Healthcare.

  • 4. Who are the leading vendors of internet of things (IoT) technologies to the Healthcare industry?

    The leading vendors of IoT technologies to the healthcare industry include AMD, Intel, Proxxi, Worldsensing, and Arm.

  • 5. How do internet of things (IoT) technologies benefit Healthcare companies?

    IoT technologies benefit healthcare companies by enabling remote patient monitoring, telemedicine, and digital health solutions. IoT tools can also be used in the pharma industry, from manufacturing processes to RPM.

  • 6. What are the challenges with adoption of internet of things (IoT) technologies in Healthcare?

    The challenges with adoption of IoT technologies in healthcare include data privacy and security concerns, lack of standardization, and high implementation costs.

  • 7. What is the projected market size of internet of things (IoT) in Healthcare?

    GlobalData forecasts that the market for IoT platforms for healthcare providers will grow at a compound annual growth rate (CAGR) of 4.6% between 2020 and 2025.

  • 8. Who are the leading specialist internet of things (IoT) vendors in Healthcare?

    The leading specialist IoT vendors across healthcare include Alteryx, Armis, McAfee, Broadcom, Oracle, Check Point Software, Okta, Cisco, Palo Alto Networks, CrowdStrike, Palantir, Dataiku, Qualcomm, Darktrace, and Securonix.

  • 9. What are the components of the internet of things (IoT) value chain?

    The components of the IoT value chain include the device layer, connectivity layer, data layer, app layer, and services layer.